At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ETNB 89Bio, Inc.
Trading 11-15 15:33:39 EST
7.94
-0.81
-9.26%
High8.85
Low7.85
Vol1.01M
Open8.85
D1 Closing8.75
Amplitude11.43%
Mkt Cap933.60M
Tradable Cap632.25M
Total Shares117.58M
T/O8.13M
T/O Rate1.26%
Tradable Shares79.63M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
89bio announces new analyses of data from Phase 2b ENLIVEN trial
89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.